Entity
  • ENDODIAG

    Created in 2011
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    281 1,621
  • Activities

  • Technologies

  • Entity types

  • Location

    75014 Paris, France

    Paris

    France

  • Employees

    Scale: 2-10

    Estimated: 9

  • SIREN

    529900532
  • Engaged corporates

    6
    4 0
  • Added in Motherbase

    4 years, 2 months ago
Description
  • Value proposition

    Founded in 2011, Endodiag is specialized in the development of products and services aimed at improving the diagnosis of endometriosis, a complex and poorly known disease, affecting yet 10% of women of reproductive age (over 180 million patients worldwide!). Located in Evry, France, within Genopole, the French largest Biocluster, the company leverages the experience of its scientific cofounders who have been working in this field for over 20 years and a network of major hospital centres both in France and abroad.

    Although endometriosis is a major cause of subfertility (40% of affected patients are infertile) and chronic pain, it takes an average 8 to 10 years between the onset of the disease and its diagnosis, currently only achieved through surgery.

    With its EndoGram® prognosis program, Endodiag contributes to improving current diagnostic practice by providing additional biological information for a personalized medical and therapeutic management for each patient. In parallel, the company develops a new non-invasive diagnostic test making endometriosis detection much easier and faster. Finally, Endodiag offers drug testing services to pharmaceutical companies enabling them to make early in-vitro evaluation of drug efficacy of cell lines and patient-derived cell cultures.

    In 2013, Endodiag actively contributed to the launch of oz2020, the first Endometriosis Observatory in France (www.oz2020.com). This observatory will help gather precise epidemiologic data on the disease and patients’ quality of life in order to advance and support scientific research, but also to raise endometriosis awareness.

    Learn more about Endodiag at www.endodiag.com

    Endométriose, Diagnostic, and Biomarqueurs

  • Original language

    Fondée en 2011, Endodiag est spécialisée dans le développement de produits et services visant à améliorer le diagnostic de l’endométriose, maladie gynécologique complexe et mal connue qui touche pourtant 10% des femmes en âge de procréer (plus de 180 millions de patientes dans le monde). Implantée sur le site de Genopole à Evry, la société s’appuie sur l’expérience de ses fondateurs qui travaillent depuis plus de 20 ans sur cette maladie et sur un réseau de centres hospitaliers majeurs en France et à l’international.

    Cause majeure d’infertilité (40% des femmes atteintes ne pourront jamais avoir d’enfant), et de douleurs chroniques souvent invalidantes, il faut pourtant un délai moyen de 10 ans diagnostiquer l’endométriose, acte réalisé par chirurgie sous anesthésie et son diagnostic médical, aujourd’hui effectué par chirurgie.

    A travers notre programme EndoGram®, nous contribuons à l’amélioration du diagnostic actuel afin de permettre un meilleur suivi médical des patientes. En parallèle, nous développons un nouveau test de diagnostic in vitro pour permettre une détection plus précoce, plus simple et non invasive. Nous proposons également aux sociétés pharmaceutiques un service de drug testing permettant d’évaluer in-vitro l’efficacité de médicaments sur des lignées et des cultures cellulaires issues de lésions d’endométriose.

    Endodiag a par ailleurs activement contribué au lancement en 2013 d’oz2020 (www.oz2020.com), le premier observatoire de l’endométriose en France. Cet observatoire a pour objet de fournir des données précises sur la maladie et les patientes afin d’aider la recherche mais aussi d’organiser des campagnes de sensibilisation.

    Pour en savoir plus sur Endodiag: www.endodiag.com

  • Endodiag - The endometriosis diagnosis expert

    Endodiag takes part in endometriosis research by developing diagnosis solutions focused on patient screening and individual endometriosis characteristics. Our innovative solutions are offered to health care professionals to adapt health care strategy according to each patient.

  • https://www.endodiag.com/
Corporate interactions BETA
Corporate TypeTweets Articles
MGEN
MGEN
Insurance
MGEN
Insurance
Other

28 Feb 2023


Paris Biotech Santé
Paris Biotech Santé
Startup accelerator & VC, Civic and Social Organizations
Paris Biotech Santé
Startup accelerator & VC, Civic and Social Organizations
Other

18 May 2023


BNP Paribas
BNP Paribas
Bank, Banking
BNP Paribas
Bank, Banking
Other

24 Jul 2017


European Commission
European Commission
European Union, Environmental Services
European Commission
European Union, Environmental Services
Not capitalistic
Not partnership
Event

15 Apr 2019


MEDICALPS
MEDICALPS
Business Consulting and Services
MEDICALPS
Business Consulting and Services
Not capitalistic
Partnership
Not event

19 Jan 2024


Bpifrance
Bpifrance
Bank, Banking
Bpifrance
Bank, Banking
Other

1 Feb 2017


Similar entities
Loading...
Loading...
Social network dynamics